Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results
November 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly...
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans
November 02, 2021 16:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a...
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions
October 28, 2021 08:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
October 21, 2021 09:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
October 15, 2021 09:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a...
Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
August 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating...
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
May 11, 2021 16:47 ET
|
Interpace Biosciences, Inc.
● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business ● Q2 Revenue Expected to Exceed $11 million ● On Track to Exceed Full Year 2021...
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
May 03, 2021 08:00 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value
April 22, 2021 08:00 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make...
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
April 05, 2021 16:05 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...